Thomas Patrick Kelly
Chief Financial Officer · Xenon Pharmaceuticals Inc.
- 2025
- Oct 1, 2026
- 2
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Thomas Patrick Kelly files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Ian Mortimer - $21.42M in XENE purchases and sales in the last 12 months
- Christopher John Kenney - $670K in XENE purchases and sales in the last 12 months
- Steven Gannon - $641K in XENE purchases and sales in the last 12 months
- Andrea Difabio - $231K in XENE purchases and sales in the last 12 months
- Gary Patou - $70K in XENE purchases and sales in the last 12 months
- Gillian Cannon - $63K in XENE purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Thomas Patrick Kelly?
Thomas Patrick Kelly is a corporate insider, tracked as Chief Financial Officer of Xenon Pharmaceuticals Inc. (XENE). InsiderAlpha holds 2 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Thomas Patrick Kelly submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Thomas Patrick Kelly been buying or selling stock?
Recorded transactions: 1 open-market purchase ($560K) and 0 open-market sales across all tracked filings.
